Search Clinical Trials
Completed
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (External Link)
Three different doses of CTL will be evaluated: dose level I: 2 x 10e7/m2; dose level II: 5 x 10e7/m2; dose level III: 1 x 10e8/m2 Day 1 YTH 24/54 …
Baylor Role:
Lead Sponsor
Completed
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (External Link)
ALASCER (Part 1 of 2) We will generate autologous (or syngeneic) or allogeneic LMP2A-specific cytotoxic T-cells and adoptively transfer them to patients with relapsed EBV-positive Hodgkin's or non-Hodgkins Lymphoma or …
Baylor Role:
Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation (External Link)
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role:
Lead Sponsor
Completed
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (External Link)
Patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells …
Baylor Role:
Lead Sponsor
Completed
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (External Link)
This is a phase I trial to assess the safety of a dose escalation of hCD40L-expressing autologous tumor cells with a fixed dose of recombinant hIL-2 gene transduced autologous leukemic …
Baylor Role:
Lead Sponsor
Completed
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells (External Link)
Before starting treatment some of the cancer cells will be taken from the patient and separated in the laboratory. A specially produced human virus (adenovirus) that carries the IL-2 gene …
Baylor Role:
Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease (External Link)
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role:
Lead Sponsor
Completed
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H (External Link)
This is a two arm study in which outcomes will be assessed independently in recipients of HLA matched sibling transplants and recipients of unrelated or mismatched family donor transplants, although …
Baylor Role:
Lead Sponsor
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (External Link)
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role:
Lead Sponsor
Completed
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy (External Link)
Tumor cells from subjects with high-risk neuroblastoma will be obtained at the time of presentation and initial diagnosis, during routine surveillance of bone marrow disease status, or at the time …